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Abstract
The human major histocompatibility complex class II isotype HLA-DR is
currently used as an activation marker for T cells. However, whether an
endogenous protein expression or a molecular acquisition accounts for the
presence of HLA-DR on T cells remains undetermined and still controversial. To
further characterize this phenomenon, we compared several aspects of the
presence of the HLA-DR protein to the presence of associated mRNA (HLA-
DRB1), focusing on human T cells from peripheral blood of healthy individuals.
Using a flow cytometric approach, we determined that the HLA-DR observed on
CD4+ T cells was almost exclusively cell surface-associated, while for autologous
CD19+ B cells, the protein could be located in the plasma membrane as well as in
the cytoplasm. Moreover, negligible expression levels of HLA-DRB1 were found
in CD4+ T cells, using an HLA-DRB1 allele-specific qPCR assay. Finally, the
presence of HLA-DR was not confined to activated CD4+ and CD8+ T cells, as
evaluated by the co-expression of CD25. The functional role of the HLA-DR
molecule on T cells remains enigmatic; however, this study presents evidence of
fundamental differences for the presence of HLA-DR on T cells from HLA-DR in
the context of antigen-presenting cells, which is a well-known phenomenon.
Although an inducible endogenous protein expression cannot be excluded for the
T cells, our findings suggest that a re-evaluation of the HLA-DR as a T cells
activation marker is warranted.
Introduction
It has been observed for more than four decades that T cells
in peripheral blood can present MHC class II (MHCII)
molecules on their outer surface and that the number of
MHCII+ T cells increases upon activation [1–4]. In line
with this, one of the three human MHCII isotypes, called
HLA-DR, is frequently used as a T cell activation
marker along with other molecules, such as CD69 and
CD25 [5–8]. Nonetheless, the functional role and
significance of HLA-DR on human T cells is not fully
determined and the unequivocal confirmation of an
endogenous expression or a protein acquisition from other
immune cells is absent. The constitutive expression of
HLA-DR is limited to a few cell types, collectively called
antigen-presenting cells (APCs) [9, 10]. These cells use
HLA-DR to present antigenic peptides to CD4+ T cells,
and consequently, HLA-DR is involved in many facets of
immune homoeostasis such as T cell activation, peripheral
tolerance and induction of apoptosis [11].
Since the first observations of HLA-DR on T cells in the
late 1970s, a number of studies have investigated aspects of
the HLA-DR molecule in this particular context. Although
still a subject of discussion, the general understanding is
that the presence of this protein complex can be explained
by either of two scenarios. The first involves an inducible de
novo, endogenous protein synthesis, while the other
encompasses a molecular acquisition from other immune
cell types by currently unverified mechanisms. The studies
supporting the former explanation have investigated
several of the components involved in HLA-DR expression,
transport and function, including lysosomal proteases [12],
antigen presentation [13, 14] and engagement of CIITA
[10, 12, 15], which is reported as the master regulator of
HLA-DR expression [16–19]. Mouse T cells do not
produce MHCII, which has been explained by a lack of
CIITA expression [20]. However, even when CIITA is
absent, MHCII expression is still observed for several cell
types [21, 22]. The second phenomenon explaining HLA-
DR on T cells is investigated in several other studies,
demonstrating a transfer of a fully functional protein
complex from APCs [23, 24]. In accordance with this, the
MHCII observed on mouse T cells is a result of an
acquisition from APCs [25–27]. In addition, a number of
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studies have found that activated rat T cells can both
synthesize and absorb MHCII molecules from adjacent cells
[28–30]. The transfer of HLA-DR to human T cells has
also been reported [31, 32], but a possible link between this
acquisition and a potential endogenous expression of HLA-
DR remains to be investigated.
Our study aimed to further explain the phenomenon of
HLA-DR on human T cells in peripheral blood of healthy
individuals. We addressed several aspects of the presence of
the protein on T cells and correlated this with a transcript
analysis of the corresponding mRNA. Moreover, the
validity of HLA-DR as a T cell activation marker was
investigated. The study was carried out to elucidate the
physiological details of HLA-DR on T cells as well as to
obtain novel information about a possible endogenous
expression. Firstly, our results indicate that HLA-DR on
CD4+ T cells in peripheral blood could not be explained by
a concurrent presence of an active protein synthesis. This
points to important differences between the HLA-DR in
the context of T cells as compared to APCs, which may be
important, when deciphering the possible functions of
HLA-DR-presenting T cells. In addition, we demonstrated
that HLA-DR was not confined to activated T cells, thus
suggesting to reassess the use of HLA-DR as an activation
marker for T cells without any accompanying information.
Methods
Antibodies. The following conjugated antibodies were
obtained from BD Biosciences (Mountain View, CA,
USA): anti-CD3-PE (SK7), anti-CD3-PerCP (SP34-2),
anti-CD4-APC-H7 (SK3), anti-CD4-PE (RPA-T4), anti-
CD8-PerCP (SK1), anti-CD8-PerCP-Cy5.5 (SK1),
anti-CD14-PE-Cy7 (M5E2), anti-CD19-APC (HIB19),
anti-CD19-PE (4G7), anti-CD19-PerCP-Cy5.5 (SJ25C1),
anti-CD25-FITC (2A3), anti-HLA-DR-FITC (G46-6),
mouse IgG1-APC-H7 (X40), mouse IgG1-FITC (MOPC-
21), mouse IgG2a-FITC (27-35), mouse IgG1-PE (MOPC-
21), mouse IgG2a-PE (MOPC-173), mouse IgG1-PerCP
(MOPC-21), mouse IgG1-PerCP-Cy5.5 (MOPC-21) and
mouse IgG1-PE-Cy7 (MOPC-21). From BD Biosciences,
the unconjugated anti-CD3 (HIT3a) was also acquired.
Anti-CD45-FITC (T29/33), anti-HLA-DR-PE (AB3) and
mouse IgG1-APC (DAK-GO1) were purchased from Dako
A/S (Glostrup, Denmark). Anti-HLA-DR-Alexa Fluor (AF)
488 (L243), anti-HLA-DR-AF647 (L243), mouse IgG2a-
AF488 (MOPC-173) and mouse IgG2a-AF647 (MOPC-
173) were purchased from BioLegend (San Diego, CA,
USA). Mouse IgG1-PerCP-Cy5.5 (P3.6.2.8.1) was
obtained from eBioscience (San Diego CA, USA). The
goat anti-mouse IgG-AF555 was purchased from Invitro-
gen (Life Technologies, Carlsbad, CA, USA).
Cells and isolation. Venous peripheral blood was obtained
from healthy donors with known HLA types. Each blood
donor had signed awritten consent form, allowing for the use
of his or her blood for research purposes. The procedure was
approved by local ethics legislation. The blood was collected
in heparinized tubes (Vacuette, Lithium Heparin; Greiner
Bio One, Frickenhausen, DE). Isolation of Peripheral blood
mononuclear cells (PBMCs) was accomplished using Lym-
phoprepTM gradient centrifugation (Axis-Shield, Oslo, Nor-
way). The PBMCs were either used directly after the
isolation or stored at 140 °C in a storage medium [RPMI
1640 (Gibco, Life Technologies), 40% heat-inactivated
foetal calf serum (FCS; Gibco), 10% DMSO (Merck
Millipore, Darmstadt, Germany), 100 U/ml penicillin/
10 lg/ml streptomycin (Ampliqon, Odense, Denmark)].
The CD4+ T cells were isolated from PBMCs using the
Dynabeads CD4 Positive Selection kit (Invitrogen) accord-
ing to the manufacturer’s guidelines. As an additional
purification step, any residual B cells were removed from the
isolated CD4+ T cells by positive selection, using Dyn-
abeadsCD19 Pan B (Invitrogen). The purity of the isolated
CD4+ T cells was evaluated by staining with fluorochrome-
conjugated antibodies with subsequent flow cytometric
analysis. From the CD4+ depleted PBMCs, CD19+ B cells
were isolated using the DynabeadsUntouchedTM Human B
Cells kit (Invitrogen) according to the manufacturer’s
guidelines.
Detection of cell surface-associated and intracellular markers
by flow cytometry. For the detection of cell surface-associated
and intracellular HLA-DR, 1 9 106 PBMCs were stained
with antibodies against CD3, CD19, HLA-DR (L243-
AF488) or the corresponding isotype control antibodies
(30 min, room temperature (RT)). Subsequently, 100 ll of
fixation medium (reagent A) from FIX & PERM Cell
Fixation and Permeabilization Kit (Invitrogen) was added
(15 min, RT). Following one wash with PBS (Gibco), a
second antibody against HLA-DR (L243-AF647), or the
corresponding isotype antibody, and 100 ll of permeabi-
lization medium (reagent B) were added to the cells
(20 min, RT). Finally, the cells were washed once with
PBS prior to flow cytometric analysis. For the detection of
cell surface-associated HLA-DR on CD4+ and CD8+ T
cells, the procedure only included the primary surface
staining, using antibodies against CD3, CD4, CD8, CD25
and HLA-DR (L243-AF647).
The flow cytometric analysis of stained cells was
performed on a FACSCanto A using FACSDIVATM software
(version 6.1.3; BD Biosciences). Calibration and compen-
sation settings for the cytometer were obtained each day
using the 7-Color Setup Beads (BD Biosciences) and once a
week with the FACSDIVATM CS&T Research Beads (BD
Biosciences). The analysis of the data was carried out with
the FLOWJO software (version 10.0.7; FlowJo LLC, Ashland,
OR, USA). Negative isotype controls were utilized to
identify the positive events. The controls were either
combined in a single tube or part of a ‘fluorescence minus
one’ (FMO) tube [33]. The median fluorescence intensity
(MFI) was the statistical value of choice.
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Detection of cell surface-associated and intracellular HLA-DR
by confocal microscopy. For all experiments, 1.5 9 105
isolated CD4+ T cells or CD19+ B cells were left to
adhere to poly-L-lysine-coated slides (Sigma-Aldrich, St.
Louis, MO, USA; 20 min, RT). The T cells were initially
stained with anti-CD3 (HIT3a; 1:250; 45 min, RT),
followed by incubation with secondary antibody (goat anti-
mouse IgG-AF555; 1:200; 45 min, RT). Slides were
washed three times in PBS and cells were fixed in 2%
paraformaldehyde (PFA) (Sigma-Aldrich) (15 min, RT).
Both T and B cells were then stained with anti-HLA-DR-
AF488 (L243) (1:100; 45 min, RT). Slides were washed
three times in PBS and cells were fixed in 2% PFA
(15 min, RT) followed by another round of washing and
permeabilization with permeabilization buffer [1% bovine
serum albumin (BSA; Sigma-Aldrich), 0.1% saponin
(Sigma-Aldrich), PBS; 8 min, RT]. To visualize cytosolic
HLA-DR, cells were subsequently stained with anti-HLA-
DR-AF647 (L243) (1:100 in permeabilization buffer;
45 min, RT). Slides were washed four times in PBS and
mounted with mounting medium (Sigma-Aldrich). Images
were captured with a Leica TCS SP5 confocal laser scanning
microscope (Leica, Wetzlar, Germany) and a 1009 oil
immersion objective using the LAS AF software (Leica). All
images were slightly adjusted for background fluorescence
and signal intensity using IMAGEJ (version 1.48; NIH,
Bethesda, MD, USA).
Total RNA extraction and cDNA synthesis. Total RNA
was extracted from the isolated CD4+ T cells and CD19+ B
cells using the TRIzol extraction method (Invitrogen). The
A260/A280 ratio was determined using a NanoDrop 1000
Spectrophotometer (Thermo Scientific, Waltham, MA,
USA). Total cDNA for the quantitative PCR (qPCR) was
generated from 1 lg total RNA from all samples using a
mixture of poly-T and random primers with SuperScript
VILO cDNA Synthesis Kit (Invitrogen) at a temperature
profile of 25 °C for 10 min, 42 °C for 60 min and 85 °C
for 5 min according to the manufacturer’s guidelines.
Quantitative PCR. PCR primers for amplification of
57–136-base pair gene-specific PCR products were used
from conserved regions of the four studied genes (HLA-
DRB1*03, CD19, B2M, and GUSB). Primers and FAM-
labelled minor groove binder (MGB) TaqMan probes were
used to detect the RNA expression level of the reference
genes B2M and GUSB [34] and the target gene HLA-
DRB1*03 for which the HLA-DRB1*03:01:01:01
mRNA sequence from the IMGT/HLA database was used
as target sequence. Expression levels of CD19 were
detected using 209 probe assays mix (Life Technologies).
The information about primer and probe sequences is
given in Table 1. The qPCR assay was applied to evaluate
the gene expression profiles of the four genes, and the data
were analysed using the QuantStudio 12K Flex system
(Life Technologies). The real-time PCR reactions were
performed in a final volume of 25 ll, containing 1 ll
cDNA solution, 12 ll Master Mix (TaqMan Universal
PCR Master Mix; ABI, Darmstadt, Germany), 0.05 lM
probe and 0.9 lM of forward and reverse primers. The
PCR reaction for TaqMan gene expression assays con-
tained 1 ll cDNA solution, 12 ll Master Mix and
1.25 ll TaqMan gene expression assay. Reactions were
made up to a final volume of 25 ll with sterile water. All
experiments were performed in triplicate and the real-time
PCR protocol was as following: denaturation by a hot
start at 95 °C for 10 min, followed by 50 cycles of a two-
step program (denaturation at 95 °C for 15 s and
annealing/extension at 60 °C for 1 min). For all the
included gene targets, only the threshold cycle (Ct) values
below 40 were included in the subsequent data analysis.
Gene expression of the target gene was normalized to the
mean Ct of B2M and GUSB applying the formula 2DCt,
where DCt = Ct target gene – Ct reference genes. The
normalization, using the mean of the two reference genes,
could be applied as target and reference genes were
amplified with comparable efficiencies (data not shown).
Statistical analysis. The statistical analysis of data from
both qPCR and flow cytometry experiments was performed
using SIGMAPLOT (version 11; Systat Software Inc., San Jose,
CA, USA). A paired or unpaired t-test was applied to test
for differences between the groups of cells from the same
individual or between two individuals, respectively. For
non-normally distributed data, the corresponding nonpara-
metric analysis was applied. Differences between groups
were considered statistically significant, when P < 0.05.
Unless otherwise specified, the data are presented as
mean  SEM.
Results
Identification and separation of HLA-DR on the cells surface
and in the intracellular compartment of CD3+ T cells
We initially wanted to investigate the cellular distribution
of the HLA-DR antigen both on the cell surface/plasma
membrane (HLA-DR mem) and in the intracellular space
(HLA-DR IC) of CD3+ T cells using flow cytometry. A
two-step strategy was developed, including an initial
staining of HLA-DR mem was followed by fixation,
permeabilization of the plasma membrane and a secondary
staining of HLA-DR IC. To separate the two separate
HLA-DR localizations, two anti-HLA-DR antibodies of
the same clone, but with different fluorophores conjuga-
tions, were applied (anti-HLA-DR mem AF488; anti-
HLA-DR IC AF647). The distribution of HLA-DR mem
and HLA-DR IC in CD3+ T cells was compared to the
distribution in CD19+ B cells, as the HLA-DR expression
pattern in this APC is well characterized. Our flow
cytometric assay necessitated a number of analytical and
experimental controls to ensure the validity of such an
approach.
 2016 The Authors. Scandinavian Journal of Immunology published by John Wiley & Sons Ltd on behalf of
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For the analysis, the gating control called the FMO [33]
was applied to identify the HLA-DR mem and HLA-DR
IC-positive events (Fig. 1). This approach is very useful for
resolving weakly stained cells in multicolour panels in flow
cytometry analyses [35, 36]. It also aids in placing a gate
for a marker, which displays a continuous expression
pattern, as is the case for HLA-DR on T cells. The applied
FMO included a tube containing all markers and replacing
the HLA-DR antibody of interest with an isotype control
antibody. In this way, the HLA-DR single and double
positive events could be determined, as exemplified in
Fig. 1.
To verify the experimental setup, in which the plasma
membrane-associated HLA-DR mem could be separated
from the intracellular HLA-DR IC, it was essential to
demonstrate and validate that a saturation of HLA-DR
mem was obtained with the initial staining step. Hence, a
saturation control was included in which all antibodies and
staining conditions were applied, only omitting the
permeabilization agent. Consequently, the HLA-DR IC
signal should be absent in this sample if both the HLA-DR
mem staining had saturated all cell surface-associated
HLA-DR and no HLA-DR IC antibody entered the cell
(Fig. 2). Initially, the optimal amount of applied anti-
HLA-DR mem (L243-AF488) was determined with an 8-
point titration experiment (0.025–4 lg; data not shown).
The optimal amount (1 lg) was applied for staining with
both anti-HLA-DR antibodies. For the saturation control
experiments, it was observed as a general feature that a
small HLA-DR IC signal could be detected in the
saturation control for both the CD3+ HLA-DR mem+ T
cells and CD19+ HLA-DR mem+ B cells (Fig. 2B).
However, for the CD3+ T cells, this signal never surpassed
the HLA-DR IC signal from the fully stained sample.
Similar observations were made for the CD19+ B cells. A
doubling of the applied amount of both HLA-DR
antibodies did not increase or decrease the recorded
intensities and cellular distributions of these markers (data
not shown).
As a final investigation, the antibody staining procedure
applied in the flow cytometric analysis was tested in a
confocal microscopy setting. The purpose of this qualita-
tive analysis was to visualize the separation of the
fluorescence signals obtained, when targeting HLA-DR
mem and HLA-DR IC with two different anti-HLA-DR
antibodies. In contrast to the flow cytometric analysis, in
which CD3+ T cells and CD19+ B cells from peripheral
blood were the target cells, isolated CD4+ T cells and
CD19+ B cells were used for the confocal microscopy
investigation. With these cells, it was shown that CD4+ T
cells presenting HLA-DR mem could be identified
(Figure S1A, top panel). In contrast, CD4+ T cells
presenting both HLA-DR mem and HLA-DR IC were
almost absent (Figure S1B). To ensure that the observed
HLA-DR signals in the CD4+ T cell population were not
due to contaminating APCs, such as monocytes, the
identification of these T cells included a CD3 antibody. For
the CD19+ B cells, the HLA-DR proteins were present in
both the plasma membrane and intracellular compartment
of the entire cell population (Figure S1A, bottom panel).
The purity of the isolated CD4+ T cells and CD19+ B cells
was 97.6  2.2% and 96.6  0.4%, respectively, as
determined by flow cytometry (n = 2; data not shown).
Dimorphic distribution of HLA-DR in the plasma membrane
and intracellular compartment of CD3+ T cells and CD19+ B
cells
Based on the abovementioned staining and gating strategy
and experimental approach, we identified the fraction of
CD3+ T cells from peripheral blood in which HLA-DR
could be found in either the plasma membrane or the
intracellular compartment or in both. An identical proce-
dure was carried out for autologous CD19+ B cells, to
ensure a positive reference. The presence of HLA-DR mem
on CD3+ T cells and CD19+ B cells differed significantly in
terms of the percent-wise distribution. For the T cells,
18.2  4.2% CD3+ HLA-DR mem+ cells were identified,
while this number was 98.8  0.5 for the B cells (n = 10).
The associated P-value was 0.002. Moreover, the corre-
sponding median fluorescence intensity (MFI) values were
also markedly different with a nearly 14 times greater MFI
Table 1 Primer and probe sequences, assay id and amplicon size for the genes analysed by qPCR.
Gene Primers FAM-labelled MBG probe
Amplicon
size
Exon
boundary
HLA-DRB1*03 F: 50-CACCTATTGCAGACACAA-30 50-ACCTTAGGATGGACTCGC-30 136 2–3
R: 50-AACCACTCACAGAACAGA-30
B2M F: 50-GAGTATGCCTGCCGTGTG-30 50-CCTCCATGATGCTGCTTACATGTCTC-30 109 3
R: 50-AATCCAAATGCGGCATCT-30
GUSB F: 50-GAAAATATGTGGTTGGAGAGCTCATT-30 50-CCAGCACTCTCGTCGGTGACTGTTCA-30 100 11–12
R: 50-CCGAGTGAAGATCCCCTTTTTA-30
CD19 Hs01047410_g1 57 1–2
F, forward; R, reverse.
The specificity of the HLA-DRB1*03 assay is located in the forward primer. For B2M, the forward primer is located in exon 2 and reverse primer in exon 4.
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value detected for the CD19+ B cells (23,047  2059)
than the equivalent value for the CD3+ T cells
(1662  138). For the CD3+ T cells, 17.9  2.5% of
the CD3+ HLA-DR mem+ cells also contained HLA-DR
IC. This was significantly higher for the CD19+ B cells
(96.9  0.9; P < 0.001). Here, the MFI for HLA-DR IC
in the CD19+ B cells (9227  596) was approximately
5.5-fold higher compared to the MFI for the CD3+ T cells
(1748  152). Finally, the analysis identified 3.0  0.7%
CD3+ HLA-DR IC+ and these were all HLA-DR mem+
(Fig. 3A). The corresponding CD19+ HLA-DR IC+ B cells
amounted to 95.9  1.2% and these were also all HLA-
DR mem+. To investigate whether the T cells, which
presented cell surface-associated HLA-DR to the greatest
extent, also carried the largest amount of HLA-DR IC, a
correlation for HLA-DR in the two compartments was
Figure 1 Improved flow cytometric gating strategy identifies HLA-DR in the plasmamembrane and intracellular compartment of CD3+ T cells and CD19+
B cells. Initially, the lymphocyte population was gated in a forward scatter/side scatter plot. From the lymphocytes, the CD3+ T cells and CD19+ B cells were
subsequently gated. Subsequently, the CD3+ HLA-DR mem+ (17%) and CD19+ HLA-DR mem+ (99.7%) populations were identified with pre-defined
gates set using the fluorescence minus one (FMO) control for HLA-DR mem. In the last step, it was determined, which HLA-DRmem+ cells also carried the
HLA-DR protein intracellularly. For this purpose, gates set with the FMO controls were used, identifying the double positive CD3+ HLA-DR mem+ HLA-
DR IC+ (15.6%) and CD19+ HLA-DR mem+ HLA-DR IC+ (95.2%) populations. For all the FMO controls, the threshold was set so that a maximum of 1%
of the events fell into the double positive quadrant. The plots are from one donor as a representative example of the 10 included donors.
 2016 The Authors. Scandinavian Journal of Immunology published by John Wiley & Sons Ltd on behalf of
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made. This revealed that a positive correlation between
these two proteins existed, both for CD3+ T cells and
CD19+ B cells (Fig. 3B).
Relative contribution of CD4+ and CD8+ T cells to CD3+ HLA-
DR mem+ T cell subset
In addition to the results about the presence of HLA-DR
mem and HLA-DR IC for CD3+ T cells, it was
investigated to which extent CD4+ and CD8+ T cells each
contribute to the CD3+ HLA-DR mem+ subset. Accord-
ingly, CD3+ CD4+ HLA-DR mem+ and CD3+ CD8+
HLA-DR mem+ T cells (hereafter referred to as CD4+
HLA-DR mem+ and CD8+ HLA-DR mem+ T cells) were
identified in a flow cytometric analysis of PBMCs. The
presence of HLA-DR mem was evaluated for these cells
(Fig. 4A, top panel) using the FMO approach described in
Fig. 1. This resulted in the detection of 8.9  1.6% CD4+
Figure 2 Comparison of HLA-DR IC signal
in CD3+ T and CD19+ B cells with/without
permeabilization of the outer plasma
membrane. To test for saturation of cell
surface HLA-DR (HLA-DR mem) with the
initially applied anti-HLA-DR antibody, a
saturation control was made for all the
included donors. For the control, the entire
staining setup was applied, only omitting the
permeabilization agent. Subsequently, the
gating strategy displayed in Fig. 1 was
applied to identify the CD3+ HLA-DR
mem+ T cells and CD19+ HLA-DR mem+ B
cells. (A) The histograms show the HLA-DR
IC signals for the HLA-DR mem+ cells for the
fully stained sample and the saturation control.
The histograms are a representative example of
the 10 donors included in the study. (B) For all
the 10 donors, there was a detectable HLA-DR
IC signal present in the saturation control for
both the CD3+ T cells and the CD19+ B cells.
However, this signal was always lower than the
specific HLA-DR IC signal detected in the
fully stained sample.
Figure 3 Correlation between HLA-DR mem and HLA-DR IC in CD3+ T cells and CD19+ B cells. (A) The distribution of HLA-DR mem and HLA-DR
IC determined by flow cytometry for CD3+ T cells and CD19+ B cells. The circle charts visualize the obtained results (n = 10). (B) The gating strategy
presented in Fig. 1 was employed to identify the HLA-DR mem+ and HLA-DR IC+ CD3+ T cells and CD19+ B cells in the presented dot plots. These
plots were made to visualize a possible correlation between HLA-DR in the two cellular compartments. Both dot plots are representative examples of the
included donors (n = 10).
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HLA-DR mem+ T cells and 18.7  3.1% CD8+ HLA-DR
mem+ T cells (n = 6). As the CD4/CD8 ratio in peripheral
blood is approximately two for adults [37, 38], the CD4+
and CD8+ T cells each contributed roughly equally to the
entire CD3+ HLA-DR mem+ T cell population.
To further characterize the HLA-DR mem-presenting
CD4+ and CD8+ T cells, the co-expression of another T cell
activation marker, CD25, was also investigated for these
cells. Of the CD4+ HLA-DR mem+, 22.8  2.3%
co-expressed CD25 (Fig. 4A, bottom panel). Additionally,
CD25 was enriched in the CD4+ HLA-DR mem+
population, when compared to the corresponding CD4+
HLA-DR mem population, for which the expression of
CD25 was 12.7  1.2% (Fig. 4B). In contrast, the CD25
expression was greatest in the HLA-DR mem– subset of the
CD8+ T cells (3.5  0.8%) as compared to the CD8+
HLA-DR mem+ T cells (1.3%  0.3).
Contrasting expression profiles of HLA-DRB1 mRNA in CD4+ T
cells and CD19+ B cells
To link the presence of the HLA-DR protein in T cells to
its transcription, an investigation of the HLA-DRB1
mRNA expression by qPCR was performed. The assay
targeted a specific allele of the most prevalently expressed
beta subunit of the heterodimeric HLA-DR protein,
namely the beta 1 (B1) chain. For the specific allele, we
chose HLA-DRB1*03 (Table 1), which is a part of the
DR52 haplotype (HLA-DRB1*03, *11, *12, *13 and *14)
[39]. The amount of HLA-DRB1 transcripts in this
haplotype is the most abundant, compared to other
haplotypes [40], making it a plentiful and advantageous
target. To ensure that only the desired target was
amplified, the HLA-DRB1*03-specific assay was initially
tested on a panel of PBMCs from 13 individuals with
HLA-DRB1 alleles representative of the major DR haplo-
types [39] (data not shown). Accordingly, the HLA-
DRB1*03-positive individuals were selected, when they
had either the homozygous HLA-DRB1*03 genotype or
the heterozygous HLA-DRB1*03/*15 genotype. For the
HLA-DRB1*03-negative samples, individuals with either
the homozygous HLA-DRB1*15 genotype or the heterozy-
gous HLA-DRB1*01/*07 were selected.
Subsequently, the expression pattern of HLA-DRB1*03
was determined for human, isolated CD4+ T cells and
CD19+ B cells from peripheral blood. As for the flow
cytometric analysis of HLA-DR mem and HLA-DR IC, the
CD19+ B cells were included as a positive control. The
qPCR analysis was performed with cells from individuals
with either a positive or a negative HLA-DRB1*03
genotype, as indicated on the section above. The results
of the expression analysis are displayed in Fig. 5A. The
difference, which was observed between CD4+ T cells and
CD19+ B cells with an HLA-DRB1*03-positive genotype,
corresponded to a 240-fold higher transcript quantity in
the B cells. No detectable signal was obtained for the
Figure 4 Contribution of CD4+ and CD8+ T cells to the CD3+ HLA-DR mem+ T cell population. The relative contribution of CD4+ and CD8+ T cells
to the CD3+ HLA-DR mem+ T cell population was investigated by staining PBMCs with antibodies against CD3, CD4, CD8, CD25, and HLA-DR mem.
(A) Using the gating strategy described in Fig. 1, the HLA-DR mem-presenting CD4+ and CD8+ T cells were identified (top panel, left). In addition, the
corresponding median fluorescence intensity (MFI) values for HLA-DR mem were obtained (top panel, right). Subsequently, the percent-wise co-expression
of CD25 was determined for the CD3+ CD4+ HLA-DR mem+ and CD3+ CD8+ HLA-DR mem+ cells (bottom panel, left) along with the corresponding
MFI (bottom panel, right). Data are presented as the meanSEM (n = 6). (B) The highest degree of CD25 expression was observed for the CD4+ T cells,
which presented the most HLA-DR mem (top panel). In contrast, CD25 was found to the greatest extent of the CD8+ T cells presenting no HLA-DR mem
(bottom panel).
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CD4+ T cells with an HLA-DRB1*03-negative genotype.
In contrast, two of the five corresponding CD19+ B cell
samples produced a detectable signal, yielding normalized
expression values in a similar range as those for the CD4+ T
cells from the HLA-DRB1*03-positive individuals. The
corresponding Ct values were 37.18  0.17 (n = 2) and
36.20  0.52 (n = 5), respectively.
As determined by flow cytometry, the purity of the
isolated CD4+ T cells was 98.8  0.37% (n = 10; data not
shown). Moreover, the presence of any cellular contamina-
tion, which could contribute to the minimally detected
mRNA signal in the CD4+ T cells from the HLA-
DRB1*03-positive individuals, was also investigated.
First, the amount of mRNA for CD19 was evaluated by
qPCR. This B cell differentiation marker was included as B
cells constitute the largest HLA-DRB1-expressing popu-
lation in PBMCs, thus encompassing the greatest source of
a possible cellular contamination. The CD19 gene tran-
scripts were approximately 1500 times more abundant in
the CD19+ B cell samples compared to the CD4+ T cell
samples, regardless of HLA-DRB1*03 genotype (data not
shown). Secondly, the presence of CD14+ monocytes was
also assessed by flow cytometry. For the investigated
samples, 0.97  0.10% CD4+ CD14+ cells could be
detected (n = 8 of the 10 included for qPCR analysis; all
the HLA-DRB1*01-positive donors were included).
Discussion
The presence of HLA-DR antigens on T cells has been
observed for more than four decades. The expression
pattern and functionality of HLA-DR is well described for
APCs but in the context of T cells, many unidentified
aspects still remain.
With the use of a stringent staining and gating strategy
for flow cytometry, this study investigated the distribution
of HLA-DR in the cellular membrane (HLA-DR mem) and
intracellular compartment (HLA-DR IC) of human CD3+
T cells from peripheral blood. As a positive reference, this
distribution was compared to that of autologous CD19+ B
cells. We hypothesized that if the cell of question
contained the functional protein in both the membrane
and intracellular compartment, it was likely that an
endogenous protein expression existed.
The flow cytometric analysis identified that approxi-
mately 18% of CD3+ T cells from peripheral blood
contained HLA-DR mem (Fig. 3A). Other studies, which
investigate HLA-DR on T cells, generally report a smaller
amount of HLA-DR mem+ T cells. However, these reports
range widely from less than 5% [37, 38] to approximately
10% [7], but also above 15% [41, 42]. Using FMO controls
[43] to set less user-biased positive gates than previously
performed, the estimation of HLA-DR+ cells is conse-
quently more accurate. The identification of a uniformly
HLA-DR mem-expressing, autologous B cell population
validated the applied strategy. For future identification of
HLA-DR on T cells, this strategy could therefore prove
very useful. Only a few per cent of all CD3+ T cells in
peripheral blood contained HLA-DR IC (Fig. 3A), and we
believe that this fraction of CD3+ T cells has not previously
been evaluated. Interestingly, a positive correlation
between HLA-DR mem and HLA-DR IC was observed
for both CD3+ T cells and CD19+ B cells (Fig. 3B).
However, not all CD3+ HLA-DR mem+ T cells were also
HLA-DR IC+ (Fig. 3A), which might be expected if an
active protein synthesis was present. Regardless, the results
obtained from the presented experiments point to signi-
ficant differences for HLA-DR in the context of T cells and
APCs of which the latter comprise a well-documented
constitutive expression of this protein.
To further investigate the link between the presence of
the HLA-DR protein on T cells to an endogenous
expression, a transcriptional analysis of HLA-DRB1 was
performed, using an allele-specific qPCR assay, targeting
the HLA-DRB1*03 allele in isolated CD4+ T cells and
CD19+ B cells. By choosing to target only one allele, it
was intended to circumvent the issues associated with the
extensive homology of the HLA-DR genes, thus providing
unambiguous expression results. With the qPCR of HLA-
DRB1*03 presented here, only minimal amounts of
transcripts could be detected in the CD4+ T cells from
HLA-DRB1*03-positive individuals, while autologous
CD19+ B cells clearly possessed an active gene transcrip-
tion of HLA-DRB1 (Fig. 5). The marginally positive
signals obtained for the T cells were very close to the
expected and inevitable non-specificity of the assay. It was
not expected that the HLA-DRB1*03-negative CD4+ T
cells could yield a similar non-specific signal, as these cells
would not produce B cell-comparable amounts of HLA-
DRB1 transcripts, given the existence of such a produc-
tion in the CD4+ T cells. Moreover, a cellular
Figure 5 Quantifying mRNA from target genes by qPCR. The
expression of HLA-DRB1*03 mRNA was investigated in isolated CD4+
T cells and CD19+ B cells from donors with an HLA-DRB1*03 positive
or negative genotype (n = 5 for each genotype). The expression of the
target gene was normalized to the mean of two reference genes (B2M and
GUSB). Data is presented as meanSEM. Statistical significant differences
are indicated with p-values; *p<0.05; **p<0.01.
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contamination with approximately 1% of residual mono-
cytes, known to express both HLA-DR [44] and CD4
[45], could very likely have contributed to the HLA-
DRB1*03 mRNA in the relevant CD4+ T cell samples. In
total, this suggests that the signal detected in the CD4+ T
cells with an HLA-DRB1*03-positive genotype could be
non-specific or ascribed to a possible cellular contamina-
tion from APCs.
When correlated with the flow cytometric analysis of
HLA-DR, the results from the qPCR assay signify that the
presence of HLA-DR on the surface of a rather constant-sized
population of circulating CD4+ T cells in healthy indivi-
duals cannot be explained by a concomitant presence of an
active gene expression. Even if the specific mRNAmay have
been partially degraded in the HLA-DR-presenting CD4+ T
cells, it can be still be reasonably expected that these cells
would give rise to a detectableHLA-DRB1mRNA signal, if
an expression was present, as they constituted roughly 9% of
the investigated cells. However, the results do not exclude
the possibility that an inducible, endogenous expression of
HLA-DR is present in these T cells. They also do not exclude
the possibility that mRNA levels and protein expression of
HLA-DR do not correlate in the investigated T cells.
Nevertheless, this study showed tendencies for circulating
HLA-DR-presenting CD4+ T cells in healthy individuals,
thus describing the physiological details of HLA-DR on T
cells. These characteristics may be different for CD4+ HLA-
DR mem+ T cells found in others tissues, such as in the
lymph nodes, where elevated levels of HLA-DR-presenting
T cells have been observed [41]. To support these theories
and to fully appreciate the presence and dynamics of HLA-
DR on human T cells, further analyses are required. These
could include activated CD4+ T cells in lymphoid tissue,
such as the palatine tonsils, or in individuals with constantly
activated T cells, such as HIV-infected patients [46].
Concomitant analysis of CIITA expression would also
further complement the HLA-DR analysis.
In classical terms, HLA-DR has been used to identify
activated T cells [5–8]. Our analyses revealed that CD4+
and CD8+ T cells each account for approximately 50% of
the entire CD3+ HLA-DR mem+ subset in peripheral
blood. However, the presence of HLA-DR mem was
seemingly not confined to activated CD4+ and CD8+ T
cells, as evaluated by a co-expression CD25 (Fig. 4A). In
effect, the expression of CD25 on the CD8+ HLA-DR
mem+ T cells was minimal, while the co-expression of the
two proteins was found to correlate to a higher degree for
the CD4+ T cells (Fig. 4B). Although both CD4+ HLA-
DR mem+ [4, 47] and CD8+ HLA-DR mem+ T cells [48]
found in peripheral blood have been associated with
regulatory functions, the difference in the expression of
CD25 presented in this study could indicate distinct
functionalities of these two cellular subsets. However,
further investigations are required to substantiate this
hypothesis.
In terms of functionality, HLA-DR on T cells has
mainly been associated with immunosuppressive signals,
inducing either apoptosis or anergy in activated T cells
[4, 49, 50]. However, reports about T cell activation can
also be found [26, 32]. Nonetheless, it seems that the
function of HLA-DR in APCs cannot simply be extra-
polated to T cells, which is based on a number of
observations from this and other studies. In the current
study, clear differences were demonstrated for the presence
of HLA-DR both at the protein and transcript level, when
comparing CD4+ T cells to CD19+ B cells. Others
describe how T cell–T cell and T cell–APC interactions
have significantly different effects on the responder T cells.
Although TCR involvement, and consequently also HLA-
DR, and co-stimulatory molecules are present for both
types of cellular interaction [50], the resulting cytokine
production (IL-2 and IL-4) and Ca2+ influx differ [49, 51,
52]. Moreover, most T cell–T cell interactions seemingly
result in the induction of anergy, further underlining these
differences [50]. In relation to key features of APCs, the
mechanism for antigen acquisition remains unidentified
for T cells [12], while other studies have investigated other
requirements of antigen presentation in these cells,
including HLA-DM, CLIP and proteolytic enzymes [12,
50]. Finally, the expression of essential co-stimulatory
molecules, including CD80 and CD86, has been investi-
gated. While some report an endogenous expression by T
cells [50], others demonstrate an acquisition of functional
molecules from APCs [32, 53, 54]. One of these studies
demonstrated a simultaneous acquisition of HLA-DR by
CD4+ T cells in a contact-dependent manner [32], but also
a contact-independent transfer of HLA-DR has been
shown [27]. It has been recognized that immune cells
are particularly prone to engage in such molecular
exchange, bestowing new functional phenotypes on the
recipient cells [55–61]. This challenges the classical
subdivision of immune cells, which is based on such
functional phenotypes, and also expands the regulatory
mechanisms of the immune system. In relation to HLA-
DR, many studies have used allogeneic stimulator cells to
activate T cells, as part of a mixed lymphocyte culture,
thereby inducing the presence of HLA-DR. However, if
acquisition of HLA-DR and other molecules can occur in
such a cell culture, it will have a major impact on future
study design and interpretation of data and possibly also
explain some of the contradictory results reported about
HLA-DR in T cells to date [50].
In this study, we further elucidated the presence of
HLA-DR on human T cells. To the best of our knowledge,
no study has to date investigated the direct HLA-DRB1
expression in human CD4+ T and CD19+ B cells from
peripheral blood and correlated it to the concurrent
presence of HLA-DR antigens in the plasma membrane
and intracellular compartment. Using this approach, we
were able to document fundamental differences between
 2016 The Authors. Scandinavian Journal of Immunology published by John Wiley & Sons Ltd on behalf of
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HLA-DR in connection with T cells and APCs in healthy
individuals, both at the protein and the transcriptional
level. Moreover, we demonstrated that HLA-DR is not
limited to activated T cells, thus challenging the use of
HLA-DR as a T cell activation marker without supple-
mentary information. Collectively, this study adds more
layers to the understanding of the presence of HLA-DR on
T cells. With a possible connection between HLA-DR and
regulatory functions of T cells, questions of a possibly
significant role of HLA-DR for T cells emerge. It also
underlines the immense complexity of one of the most
important molecules for the antigen specificity and
function of the adaptive immune system.
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